Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
$1.78
+2.3%
$1.62
$1.03
$2.41
$55.53M-0.53405,691 shs144,405 shs
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$0.00
$1.22
$8.45
$45.46M1.5329,344 shsN/A
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
$0.70
$0.54
$2.35
$13.77M2.12190,529 shs26,947 shs
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.21
-0.3%
$0.29
$0.21
$0.71
$38.46M0.8313,165 shs851 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
0.00%+2.30%+9.20%+15.58%-6.32%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00%0.00%0.00%0.00%+4,900.00%
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00%-8.48%-28.31%-47.96%-64.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
2.3779 of 5 stars
3.55.00.00.01.10.00.6
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3.00
Buy$4.50152.81% Upside
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.00
N/AN/AN/A
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
0.00
N/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NVLN, ATNM, NBRV, and PYRGF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/A$1.31 per shareN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
$35.59M0.00N/AN/A$0.10 per share0.00
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
$130.43M0.00N/AN/A($4.69) per share0.00
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M4.21N/AN/A($0.01) per share-20.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/A
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
-$108.33MN/A0.00N/AN/A-79.43%N/A-26.13%N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.03N/AN/A-115.14%N/A-60.81%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/AN/AN/AN/AN/A
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
N/AN/AN/AN/AN/A
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
N/A
10.25
10.25
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.12
0.85
0.52
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
N/A
0.24
0.21
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50

Institutional Ownership

CompanyInstitutional Ownership
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
27.50%
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
0.27%
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
35.00%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actinium Pharmaceuticals, Inc. stock logo
ATNM
Actinium Pharmaceuticals
3031.20 million29.32 millionOptionable
Nabriva Therapeutics plc stock logo
NBRV
Nabriva Therapeutics
7032.02 million31.49 millionNot Optionable
Novelion Therapeutics Inc. stock logo
NVLN
Novelion Therapeutics
10919.62 millionN/AOptionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90187.53 million96.34 millionNo Data

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results
PyroGenesis Announces Extension to Term of Warrants
PyroGenesis Announces First Quarter 2025 Results
PyroGenesis Provides Update on Fumed Silica Project

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actinium Pharmaceuticals stock logo

Actinium Pharmaceuticals NYSE:ATNM

$1.78 +0.04 (+2.30%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.78 -0.01 (-0.28%)
As of 08/29/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Nabriva Therapeutics stock logo

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Novelion Therapeutics stock logo

Novelion Therapeutics NASDAQ:NVLN

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.21 0.00 (-0.29%)
As of 08/29/2025 11:49 AM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.